Prognostic Stratification in DLBCL Patients With Aberrant MYC Gene

Authors

Jian-Rong Li
Vikram R Shaw
Abi Parthasarathy
Yong Li
Christopher I Amos
Chao Cheng

Language

English

Publication Date

11-1-2024

Journal

British Journal of Haematology

DOI

10.1111/bjh.19699

PMID

39137931

PMCID

PMC11568942

PubMedCentral® Posted Date

11-1-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease characterized by a subset of patients who exhibit treatment resistance and poor prognoses. Genomic assays have been widely employed to identify high-risk individuals characterized by rearrangements in the MYC, BCL2 and BCL6 genes. These patients typically undergo more aggressive therapeutic treatments; however, there remains a significant variation in their treatment outcomes. This study introduces an MYC signature score (MYCSS) derived from gene expression profiles, specifically designed to evaluate MYC overactivation in DLBCL patients. MYCSS was validated across several independent cohorts to assess its ability to stratify patients based on MYC-related genetic and molecular aberrations, enhancing the accuracy of prognostic evaluations compared to conventional MYC biomarkers. Our results indicate that MYCSS significantly refines prognostic accuracy beyond that of conventional MYC biomarkers focused on genetic aberrations. More importantly, we found that nearly 50% of patients identified as high risk by traditional MYC metrics actually share similar survival prospects with those having no MYC aberrations. These patients may benefit from standard GCB-based therapies rather than more aggressive treatments. MYCSS provides a robust signature that identifies high-risk patients, aiding in the precision treatment of DLBCL, and minimizing the potential for overtreatment.

Keywords

Humans, Lymphoma, Large B-Cell, Diffuse, Prognosis, Male, Proto-Oncogene Proteins c-myc, Female, Middle Aged, Biomarkers, Tumor, Genes, myc, Aged, Adult, Gene Expression Profiling, Diffuse Large B-Cell Lymphoma, MYC Rearrangement, Gene Signatures, Prognostic Stratification

Published Open-Access

yes

Recommended Citation

Li, Jian-Rong; Shaw, Vikram R; Parthasarathy, Abi; et al., "Prognostic Stratification in DLBCL Patients With Aberrant MYC Gene" (2024). Faculty and Staff Publications. 4397.
https://digitalcommons.library.tmc.edu/baylor_docs/4397